Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical colorectal cancer"
DOI: 10.1016/j.clcc.2019.03.002
Abstract: BACKGROUND No standard treatment for advanced unresectable pseudomyxoma peritonei (PMP) has been defined so far. PMP is traditionally considered chemoresistant but nonrandomized series showed promising results with regimens for gastrointestinal tumors. PATIENTS AND METHODS We… read more here.
Keywords: metronomic capecitabine; capecitabine cyclophosphamide; regimen unresectable; pseudomyxoma peritonei ... See more keywords
Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Communications"
DOI: 10.1186/s40880-018-0312-1
Abstract: BackgroundHepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death. Sorafenib, a multitarget angiogenesis inhibitor, is an approved frontline treatment for advanced HCC in Western countries, although a complete response (CR) to… read more here.
Keywords: carcinoma; capecitabine; case; metronomic capecitabine ... See more keywords
Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2021-1579
Abstract: This is an open-label, single-center, multi-cohort phase Ib trial, which consists of three cohorts, including cohort 1 (HER2 negative gastric or gastric esophageal junction adenocarcinoma), cohort 2 (esophageal squamous cell carcinoma and head and neck squamous… read more here.
Keywords: metronomic capecitabine; capecitabine patients; trial; camrelizumab metronomic ... See more keywords
Cost-effectiveness analysis of metronomic capecitabine as adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.904372
Abstract: Background Adding metronomic capecitabine to concurrent chemoradiotherapy (CCRT) brings failure-free survival (FFS) benefits to patients with locoregionally advanced nasopharyngeal carcinoma (NPC). This study assesses the cost-effectiveness of metronomic capecitabine in locoregionally advanced NPC. Methods We… read more here.
Keywords: advanced nasopharyngeal; metronomic capecitabine; capecitabine; cost ... See more keywords